INCR Intercure

InterCure to Present in Benzinga Cannabis Capital Conference

InterCure to Present in Benzinga Cannabis Capital Conference

NEW YORK and TORONTO and HERZLIYA, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that Alexander Rabinovitch, CEO of InterCure, will present at the Benzinga Cannabis Capital Conference on Thursday, October 14, 2021 at 1:50pm ET. The presentation will be shown again on October 15th at 1:50pm ET. In addition, Mr. Rabinovitch will participate in a live panel discussion titled, “International Spotlight – Continued Cannabis Expansion in European Markets” on Friday, October 15 at 2:10pm ET. To view the Company presentation, please click the following link: . To watch the live panel discussion, please click the following link: .

Management will be available for virtual one-on-one meetings with registered conference attendees. To register for the conference, please visit the conference website:

If you are interested in scheduling a one-on-one meeting with InterCure’s management team, please contact .

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: .

To be added to InterCure’s email distribution list, please email  with “InterCure” in the subject.

Contact:

InterCure Ltd.

Amos Cohen, Chief Financial Officer

KCSA Strategic Communications

Investor and Media Relations

 



EN
13/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intercure

 PRESS RELEASE

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Mill...

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year. During the second half of 2025, the Company generated its first significant revenues from the German...

 PRESS RELEASE

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Mill...

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA2, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year. During the second half of 2025, the Company generated its first significant revenues from the Germ...

 PRESS RELEASE

InterCure and Cannasoul Sign Strategic Investment and Collaboration Ag...

InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation Agreements formalize research partnership combining InterCure’s global pharmaceutical platform with Cannasoul’s world-class analytics and scientific innovation Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like InterCure NEW YORK & HERZLIYA, Israel , Nov. 03, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR...

 PRESS RELEASE

InterCure Reports First Half 2025 Results with NIS 130 Million in Reve...

InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel InterCure is encouraged by recent regulatory momentum in the U.S. and believes that it is well positioned to capitalize on evolving U.S. cannabis rescheduling, especially following its recent signing of an agreement to acquire ISHI NEW YOR...

 PRESS RELEASE

InterCure Reports First Half 2025 Results with NIS 130 Million in Reve...

InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel InterCure is encouraged by recent regulatory momentum in the U.S. and believes that it is well positioned to capitalize on evolving U.S. cannabis rescheduling, especially following its recent signing of an agreement to acquire ISHI NEW YOR...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch